Milestone Revenue was Zymeworks’s largest product and service line in fiscal 2025, bringing in $62.10M of $105.97M (59%).
| Product and Service | FY 2020 | FY 2025 |
|---|---|---|
| Milestone Revenue | $62.10M | |
| Recognition Of Deferred Revenue | $18.33M | |
| Milestone | — | |
| Upfront Fee | — | |
| Option Exercise Fee | $7.50M | |
| Research Support Payments & Other Service | $5.62M | |
| Drug Supply For Ongoing Studies | $6.55M | |
| Partner Revenue | — | |
| Other Drug Supply | $2.87M | |
| Royalties | $2.75M | |
| Research Period Extension Fee | $250.00K | |
| Total | $105.97M |
Zymeworks brought in $105.97M from its eight product and service lines in fiscal 2025, the year ended December 31, 2025. Milestone Revenue was the largest at $62.10M (58.6%), ahead of Recognition Of Deferred Revenue at $18.33M (17.3%) and Option Exercise Fee at $7.50M (7.1%). The other five lines brought in $18.03M combined.
Beone Medicines Ltd. (Previously Known As Beigene, Ltd.) ("Beone"): was Zymeworks’s largest revenue line in fiscal 2025, bringing in $39.37M of $105.97M (37%).
| Customer | FY 2024 | FY 2025 |
|---|---|---|
| Jazz: | $62.63M | $16.75M |
| Beone Medicines Ltd. (Previously Known As Beigene, Ltd.) ("Beone"): | $11.01M | $39.37M |
| Johnson & Johnson Innovative Medicine (Previously Known As Janssen Biotech, Inc.) ("Jj"): | — | $25.00M |
| Glaxosmithkline Intellectual Property Development Ltd. ("Gsk"): | $2.50M | $14.00M |
| Bristol-Myers Squibb ("Bms"): | — | $7.50M |
| Daiichi Sankyo, Co., Ltd. ("Daiichi Sankyo"): | — | $3.10M |
| Merck Sharp & Dohme Llc ("Merck") | — | $250.00K |
| Total | $76.14M | $105.97M |
Zymeworks brought in $105.97M from its seven revenue lines in fiscal 2025, the year ended December 31, 2025. Zymeworks regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $76.14M. Beone Medicines Ltd. (Previously Known As Beigene, Ltd.) ("Beone"): was the largest at $39.37M (37.2%), ahead of Johnson & Johnson Innovative Medicine (Previously Known As Janssen Biotech, Inc.) ("Jj"): at $25.00M (23.6%) and Jazz: at $16.75M (15.8%). The other four revenue lines brought in $24.85M combined.
Compared with fiscal 2024, Glaxosmithkline Intellectual Property Development Ltd. ("Gsk"): grew fastest, up 460.0% to $14.00M, while Jazz: fell the most, down 73.3% to $16.75M.
Zymeworks began breaking out Johnson & Johnson Innovative Medicine (Previously Known As Janssen Biotech, Inc.) ("Jj"): in fiscal 2025, Bristol-Myers Squibb ("Bms"): in fiscal 2025, Daiichi Sankyo, Co., Ltd. ("Daiichi Sankyo"): in fiscal 2025 and Merck Sharp & Dohme Llc ("Merck") in fiscal 2025.
Zymeworks (ZYME) reports its revenue by product and service and by customer. In fiscal 2025, Milestone Revenue was its largest product and service line, bringing in $62.10M (58.6% of the total), followed by Recognition Of Deferred Revenue at $18.33M (17.3%).
Milestone Revenue was Zymeworks' largest product and service line in fiscal 2025, bringing in $62.10M, or 58.6% of the $105.97M total across its eight product and service lines.
Beone Medicines Ltd. (Previously Known As Beigene, Ltd.) ("Beone"): was Zymeworks' largest revenue line in fiscal 2025, bringing in $39.37M, or 37.2% of the $105.97M total across its seven revenue lines.
Every figure comes from Zymeworks' annual financial filings, as reported. Each line keeps the name Zymeworks gives it, and years follow its fiscal calendar.
Zymeworks' revenue by product and service goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.